CAR-T Digest- August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest- August 2020
SOTIO acquired rights to BOXR CAR-T platform and products from Unum Therapeutics
31 Aug 2020
BOXR1030 (GPC3-targeted CAR-T cells) – SOTIO/ UNUM Therapeutics
- SOTIO acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and its lead programs (BOXR1030) for a total of $11.5 million, including $8.1 million upfront payment and potential $3.4 million in milestones
- The company will utilize Unum’s R&D data, a portion of its laboratory and manufacturing facility to establish a T cell therapy R&D Center of excellence in Cambridge, MA
- Lead program expected to initiate first clinical studies in 2021
SOTIO acquires BOXR CAR-T platform and products to strengthen portfolio
Share this
CI Scientists Remarks:
- Bolt-On Chimeric Receptor (BOXR) technology is designed to improve the functionality of engineered T cells by incorporating a “bolt-on” transgene to overcome resistance of the solid tumor microenvironment (TME) to T cell attack
- In preclinical studies, BOXR1030 was resistant to suppressive tumor microenvironment-like conditions, showing improved T cell proliferation under both hypoxic and low glucose conditions and superior efficacy in comparison to classical GPC3-targeted CAR-T cells
- IND (late 2020) studies are underway for BOXR1030 is expected to initiate first clinical studies in hepatocellular carcinoma and other solid tumors by 2021
- BOXR platform is complimentary to Sotio’s diverse portfolio: IL-15 superagonist program (targeting cancer), Cell therapy program DCVAC (Prostate, ovarian, lung cancer), Antibody drug conjugates (targeting cancer)
- Possible synergies of a CAR-T with their clinical stage SO-C101 (IL-15) program
– Jesanto Mathew, CI Scientists